Iptacopan (LNP023)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
Jul 19, 2021 → Apr 18, 2023
NCT ID
NCT04820530About Iptacopan (LNP023)
Iptacopan (LNP023) is a phase 3 stage product being developed by Novartis for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is completed. This product is registered under clinical trial identifier NCT04820530. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04820530 | Phase 3 | Completed |
Competing Products
20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Crovalimab + Placebo | Chugai Pharmaceutical | Phase 1/2 | 41 |
| Crovalimab + Eculizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Eculizumab | AstraZeneca | Phase 3 | 77 |
| Danicopan | AstraZeneca | Phase 3 | 77 |
| LNP023 | Novartis | Pre-clinical | 23 |
| iptacopan | Novartis | Phase 2 | 52 |
| LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Pre-clinical | 23 |
| Iptacopan | Novartis | Phase 3 | 77 |
| LNP023 + Eculizumab + Ravulizumab | Novartis | Phase 3 | 77 |
| LNP023 | Novartis | Phase 3 | 77 |
| LFG316 + LNP023 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| Crovalimab | Roche | Phase 3 | 77 |
| ABP 959 + Eculizumab | Amgen | Phase 3 | 76 |
| Pegcetacoplan | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| BMS-919373 + Placebo (Matching with BMS-919373) | Bristol Myers Squibb | Phase 2 | 51 |
| Humanized anti-Factor Bb monoclonal antibody + Placebo | Sanofi | Phase 1 | 32 |